Victory Capital’s August AUM Growth: 5 Key Equity Insights
Explore how Victory Capital’s August 2025 AUM climbed 1.3%, driven by equity gains and strategic moves, revealing fresh perspectives on asset management and market positioning.
Explore how Victory Capital’s August 2025 AUM climbed 1.3%, driven by equity gains and strategic moves, revealing fresh perspectives on asset management and market positioning.
Explore how NuScale Power and Nano Nuclear Energy stack up in the evolving nuclear market, revealing key insights on their technology, financials, and growth potential for savvy investors eyeing nuclear stocks.
Explore the 2025 AI infrastructure showdown between Dell Technologies and Applied Digital (APLD). Discover valuation gaps, growth drivers, and which stock suits your investment appetite in this booming sector.
Explore how Novartis’s $1.4B acquisition of Tourmaline Bio adds the Phase III cardiovascular drug pacibekitug, targeting IL-6 inflammation to reshape heart disease treatment and pipeline growth.
Discover how Ford Pro’s partnership with ServiceTitan transforms fleet management by integrating real-time vehicle data with operations software, cutting downtime and boosting efficiency for trades businesses across North America.
Discover how Onto Innovation’s Atlas G6 optical metrology system revolutionizes AI-era semiconductor process control with unmatched precision, smaller spot sizes, and faster optimization for next-gen chip manufacturing.
Discover how Ciena and REDIMadrid’s quantum-secure data transport project revolutionizes network security by integrating Quantum Key Distribution with existing fiber, safeguarding AI-driven traffic and future-proofing Madrid’s research infrastructure.
Explore 5 large drug stocks showing resilience and innovation in 2025’s challenging pharma landscape, navigating patent cliffs, tariffs, and regulatory shifts with strategic pipelines and robust growth prospects.
Discover how Ionis Pharmaceuticals’ ION582 earned FDA Breakthrough Therapy status, accelerating hope for Angelman syndrome patients with promising clinical gains and a competitive edge in rare neurological disease therapies.